Peri-X gel is designed to treat periimplantitis and peri-implant mucositis via dismantling the biofilm that causes the disease.

Recurring Inflammatory Conditions: periimplantitis and peri-implant mucositis are chronic, recurring inflammatory diseases affecting dental implant patients.

Symptoms: Periimplantitis symptoms include inflammation, bleeding, gum recession, implant mobility, and potential implant failure.

High prevalence rates: 63% for peri-implant mucositis and 20% for peri-implantitis.

Cause: Oral microbial film on exposed teeth and subgingival tissue.

Biofilm Challenge: Conventional bactericidal compounds target live flora but lack effectiveness against biofilm.

The “gold standard” treatment today is still based on mechanical anti-infective approach (scaling and root planing, SRP). The treatment may also include antibiotics, antiseptics, laser/ PDT therapy.

SRP has poor efficacy (~30% failure rate) and requires repetition on a regular basis.

The consensus is that local/topical antiseptics and antibiotic have little effect due to the formed biofilm (that prevents the active pharmaceutical ingredient from penetrating).

Peri-X addresses a critical issue both to patient and dentist, as dental implants are part of an expensive and lengthy procedure.
Peri-X is suitable for use by both dentists and hygienists.
Peri-X gel has a unique proprietary composition: Sodium Polyphosphates + N,N-Bis (carboxymethyl)-L-glutamic acid tetrasodium.

Gel: thermo-sensitive formula. Transforms instantly from liquid to gel in contact with 37°C gingiva.

Clinical Success: Demonstrates significant pocket depth reduction within 6 weeks after 1 use.

Developed in collaboration with Prof. David Polak, an esteemed periodontist from Hadassah dental school in HUJI.

The technology is Patent pending and the product is already registered and approved as a medical device.